A Phase I, Single-Institution Open Label, Dose-Escalation Trial With an Expansion Trial Cohort Evaluating the Safety and Tolerability of AZD6244 and IMC-A12 in Subjects With Advanced Solid Malignancies

Trial Profile

A Phase I, Single-Institution Open Label, Dose-Escalation Trial With an Expansion Trial Cohort Evaluating the Safety and Tolerability of AZD6244 and IMC-A12 in Subjects With Advanced Solid Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2016

At a glance

  • Drugs Cixutumumab (Primary) ; Selumetinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Sep 2014 Status changed from active, no longer recruiting to completed, according to results published in the British Journal of Cancer.
    • 14 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 10 Jan 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top